悦康药业(688658) - 2024 Q1 - 季度财报

Financial Performance - Diluted earnings per share decreased by 21.05% to CNY 0.15[4] - Net profit attributable to shareholders decreased by 18.72% due to intensified competition and declining sales and prices in certain product areas[6] - Total revenue for the first quarter of 2024 was approximately ¥967.9 million, representing a decrease of 14.24% compared to the same period last year[31] - Net profit attributable to shareholders of the listed company was approximately ¥69.3 million, down 18.72% year-over-year[31] - Net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥64.6 million, a decrease of 22.22%[31] - The company reported an operating profit of approximately ¥80.4 million, down from ¥96.3 million in the previous year[25] - The total comprehensive income attributable to the parent company was ¥69,305,423.83, compared to ¥85,267,722.97 in the previous year, reflecting a decrease[49] - Basic and diluted earnings per share were both ¥0.15, down from ¥0.19 in the same period last year[49] Cash Flow and Investments - Net cash flow from operating activities decreased by 32.73% due to lower sales and prices, resulting in reduced cash receipts compared to the same period last year[6] - Net cash flow from operating activities was approximately ¥146.1 million, reflecting a decline of 32.73% compared to the previous year[31] - Cash inflows from operating activities totaled ¥1,099,895,626.67, a decrease from ¥1,245,924,747.38 in the previous year[50] - Net cash flow from investing activities for Q1 2024 was -RMB 90.8 million, an improvement from -RMB 119.2 million in Q1 2023[56] - Net cash flow from financing activities for Q1 2024 was RMB 189.3 million, compared to -RMB 4.9 million in Q1 2023[56] - The company paid RMB 94.9 million in taxes in Q1 2024, down from RMB 118.0 million in Q1 2023[56] - The net increase in cash and cash equivalents for Q1 2024 was RMB 244.7 million, compared to RMB 94.9 million in Q1 2023[56] Assets and Liabilities - Total assets increased by 3.35% to CNY 6,109,037,390.12 compared to the end of the previous year[4] - Total liabilities rose to approximately ¥2.46 billion, compared to ¥2.31 billion in the previous year[23] - Total equity attributable to shareholders of the parent company was approximately ¥3.64 billion, an increase from ¥3.59 billion[23] - Cash and cash equivalents increased to CNY 1,732,480,753.55 from CNY 1,480,221,784.88 at the end of the previous year[21] - Accounts receivable decreased to CNY 823,928,730.81 from CNY 893,765,635.86 at the end of the previous year[21] - Inventory increased to CNY 745,064,206.15 from CNY 727,686,306.44 at the end of the previous year[21] - Other current assets increased to CNY 42,722,935.10 from CNY 39,307,764.64 at the end of the previous year[21] Research and Development - R&D investment totaled CNY 97,065,195.47, representing an increase of 10.24% year-on-year, and accounted for 10.03% of operating revenue, up by 2.23 percentage points[4] - Research and development expenses increased to RMB 85.5 million in Q1 2024, up 15.5% from RMB 73.7 million in Q1 2023[53] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,638, with the largest shareholder holding 40.05% of the shares[35] - The largest shareholder, Fuyang Jingyue Yongshun Information Consulting Co., Ltd., held 180,240,120 shares, which are currently frozen[35] - The company did not report any significant changes in shareholder relationships or agreements among shareholders[38] Accounting and Financial Standards - The company has not adopted any new accounting standards that would affect the financial statements for the current year[52] Operating Costs and Expenses - Total operating revenue for Q1 2024 was RMB 967.9 million, a decrease of 14.2% compared to RMB 1,128.6 million in Q1 2023[53] - Total operating costs for Q1 2024 were RMB 904.1 million, down 11.9% from RMB 1,026.3 million in Q1 2023[53] - Sales expenses decreased significantly to RMB 294.0 million in Q1 2024, down 33.9% from RMB 443.9 million in Q1 2023[53] - The company reported a financial expense of -RMB 539.7 thousand in Q1 2024, a significant improvement from -RMB 3.97 million in Q1 2023[53] Non-Operating Income and Expenses - The total non-operating income and expenses amounted to -¥1,075,404.24, after accounting for tax effects and minority interests[34] - The company reported a net loss attributable to minority shareholders of ¥181,138.61, contrasting with a profit of ¥265,276.34 in the previous year[49]